Participant Profile: Rubius Therapeutics
The Rubius Erythrocyte Design™ (RED) platform leverages the latest gene modification and cell culture tools to modify erythroid progenitors and differentiate them into enucleated, biotherapeutic red blood cells carrying a wide variety of clinically relevant proteins in their cytoplasm or on their surface. Partnering with Elsevier, the Rubius team hopes to accelerate the discovery process and expand the scope of their research efforts.
Rubius Therapeutics was founded by Flagship VentureLabs and is using breakthrough science to develop an entirely new class of medicines,
Red-Cell Therapeutics™ (RCTs), with the potential to address a broad array of clinical diseases in the areas of cancer, autoimmune disease, cardiovascular conditions, metabolic disorders, and infection.
Meet the team
Avak Kahvejian, Ph.D.
Founding President and CEO
Avak is a founding member of Rubius Therapeutics, as well as a partner in Flagship’s VentureLabs innovation unit, where he leads a team to invent and launch new companies and platforms in the life sciences sector. He was also a founder of VL27, Inc. a VentureLabs company that served as the basis for Codiak Biosciences, the leading exosome therapeutics company.
A breakthrough therapeutic platform such as Red-Cell Therapeutics™ requires access to a wealth of intellectual resources to make the vision a reality. The Hive provides an excellent medium for accessing Elsevier’s suite of information tools that can help any biotech startup thrive.
Robert Deans, Ph.D.
Chief Scientific Officer
With a background in cell therapy, including more than 25 years of experience in adult stem cell therapeutics and translational science, Dr. Deans is responsible for science and technology development at Rubius.
The technology nexus between protein engineering, gene therapy and cell processing is unique, and The Hive enables Rubius with information access and design tools that would otherwise be unavailable.
Vice President of Manufacturing
Robert is responsible for manufacturing and bioprocess development, based on his background in Gene Therapy and Biological Manufacturing.
As a technologist, I strive to maintain current, state of art information to assist in the continuous improvement of cell therapy manufacturing. Having access to tools provided by The Hive will enable me to accelerate that process.
Senior Vice President of Corporate Development
Nathan has 25 years of strategy, investment, and operational experience in the healthcare field, working to develop the R&D, commercial and investment strategies for many of the world’s largest biopharmaceutical companies.
As the head of corporate development, I’m excited to be able to access a wide range of tools that enable disease and target exploration, strategic prioritization and risk analysis.
Tiffany Chen, Ph.D.
Tiffany was a founding scientist at Rubius Therapeutics and helped build out the company’s platform. She develops the company’s prototyping efforts for therapeutic candidates and platform expansion, and is part of the early discovery team where she leads a group with a focus on autoimmune disease.
As a scientist developing out the therapeutic capabilities of the Red Cell Therapeutics platform, I am excited to utilize the resources provided by the Hive program. Many of the tools will help enable and ease design of our studies.
Sivan Elloul, Ph.D.
Sivan is responsible for leading Rubius’ oncology program, based on her background and experience in cancer research and in-vivo pharmacology. She has studied cancer progression (including solid tumors and hematological tumors) for more than 10 years.
I am curious to see how the tools provided by the Hive can help us do better science, combined with our unique and very promising technology.
Omid Harandi, Ph.D.
Omid is a Geneticist with specialty in stem cell biology. Currently, his team is developing novel platforms to generate therapeutic red blood cells from hematopoietic stem cells for wide range of diseases.
As a scientist trying to learn and getting inspired by nature and developing novel therapeutics, the support from the Hive program will be beneficial.
Lenka Hoffman, Ph.D.
Lenka is a founding scientist at Rubius Therapeutics, where she has been involved in establishing and developing the core platform.
With its wide array of tools and access to information, the Hive has a tremendous ability to accelerate the development of our platform and therapies for patients.
Qin Yu, Ph.D.
Qin Yu is responsible for leading the Rubius Platform Development team and therapeutic Development projects.
I am excited about accelerating the journey to bring first-in-class, groundbreaking therapies to patients, powered by the Rubius innovation engine and the information fuel from the Hive.
Drug Discovery and Development:
Learn More About Elsevier R&D Solutions for Early Stage
Improve R&D productivity with a chemistry research solution that delivers experimental facts on chemical structures, properties, reactions and procedures.
Reaxys Medicinal Chemistry
Empower hit identification and lead optimization with normalized compound–target affinity data and comprehensive pharmacokinetic, efficacy, toxicity, safety and metabolic profiles.
Increase the discovery of biomedical evidence to support critical life sciences functions, with access to the world's most comprehensive biomedical literature database.
Enable better informed preclinical drug safety decisions with comprehensive, fully searchable FDA/EMA drug approval documents and comparative extracted drug safety data.
Reduce time spent monitoring, organizing and annotating scientific and medical literature for triage and compliance reports such as PSURs and ICSRs.
Enable better understanding of biological processes underlying disease progression and treatment response, with a solution that helps researchers interpret experimental data from scientific literature.
Drive pharmaceutical research towards innovative directions by working with Elsevier's Professional Services team to resolve challenges with data quality and integration.
Get meaningful answers to complex pharma R&D research questions through Elsevier's custom Text Mining service that enables the retrieval of highly specified information from unstructured content.
Enable researchers to more effectively and efficiently search authoritative, fulltext scientific, technical and health content through the use of smart, intuitive functionality.
Help researchers discover trends, partners and experts with the world’s largest abstract & citation database of peerreviewed literature, including tools to track, analyze and visualize research.